Halozyme reports Q2 non-GAAP EPS 74c, consensus 63c

Reports Q2 revenue $221M, consensus $199.95M. “Our strong Q2 results with record revenue of $221M and non-GAAP EPS of 74c were complemented with significant commercial and clinical advancements with our ENHANZE product pipeline,” said Dr. Helen Torley, president and CEO of Halozyme. “The FDA approval for argenx’s VYVGART Hytrulo with ENHANZE for generalized myasthenia gravis expanded our commercialized partnered products to six products generating royalty revenue. In addition, argenx’s VYVGART Hytrulo achieved positive data in a second indication for CIDP and Roche’s SC ocrelizumab with ENHANZE met the phase 3 study primary and secondary endpoints, which support the near-term additional opportunities for growth. We expect our commercialized partnered products to further expand with the potential FDA approval of Roche’s SC atezolizumab later this year. We also look forward to late-stage clinical data from argenx for ITP and pemphigus, which will support our future growth trajectory. We are well positioned for another record year with our updated guidance.”